NCT06637371 - A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

May 3, 2027

Study Completion Date

May 3, 2027

Conditions

Asthma

Interventions

DRUG

AMG 691

Subcutaneous (SC) injection

DRUG

Placebo

SC injection

Trial Locations (14)

2800

RECRUITING

Algemeen Ziekenhuis Sint-Maarten, Mechelen

5000

RECRUITING

Clinical Medical and Analytical eXellence CMAX, Adelaide

27599

RECRUITING

University of North Carolina Clinical and Translational Research Center, Chapel Hill

27607

RECRUITING

North Carolina Clinical Research, Raleigh

31904

RECRUITING

ClinCept, LLC, Columbus

33157

RECRUITING

Destiny Research Center, Palmetto Bay

33180

RECRUITING

Translational Clinical Research LLC, Aventura

55114

RECRUITING

Prism Research LLC dba Nucleus Network, Saint Paul

55905

RECRUITING

Mayo Clinic, Rochester

78240

RECRUITING

Endeavor Clinical Trials, San Antonio

92630

RECRUITING

Orange County Research Center, Lake Forest

02115

RECRUITING

Brigham and Womens Hospital, Boston

K0C 2K0

RECRUITING

Winchester District Memorial Hospital, Winchester

SW10 9NH

RECRUITING

Chelsea and Westminster Hospital, London